IDDI Newsletter – November 2021
PARTNERSHIP WITH MEDIDATA
IDDI AT OUTSOURCING IN CLINICAL TRIALS DACH – BOOTH #3
We are happy to exhibit at OCT DACH – Zürich. Stop by booth 3, we would love to hear your needs! We look forward to meeting you there face to face!!
ASSESSING ACTIVITY IN EARLY-PHASE TRIALS IN ONCOLOGY: CURRENT DESIGNS FOR EXPANSION COHORTS & PHASE II
December 2 | 05:00 PM CET | 11:00 AM EDT
Learn on different types of Bayesian & frequentist designs that may be used for expansion cohorts in phase 1 trials and in single-arm and randomized phase 2 trials in oncology. More info
PHASE I TRIALS IN ONCOLOGY: PROS & CONS OF CURRENT DESIGNS Be updated on current trends in phase-1 designs in oncology.
SAMPLE SIZE RE-ESTIMATION AS AN ADAPTIVE DESIGN
by Laurence Collette, MSc, PhD, Principal Statistician, Consulting Services, IDDI
Published in Applied Clinical Trials, September 1, 2021, Volume 30, Issue 9.
IMMUNOTHERAPY AGAINST CANCER: CHALLENGES & OPPORTUNITIES
by Dr Everardo Saad, Medical Director, IDDI and Serge Bodart, CCO, IDDI
Published in Drug Discovery & Development, July 26, 2021
IDDI 30 YEAR ANNIVERSARY
2021 marks IDDI’s 30 Year Anniversary!
We are truly grateful to the 350+ pharmaceutical and biotech companies, as well as academic cooperative groups and CROs worldwide who have entrusted us the planning and management of more than 1200 clinical trials.
Today, with over 30 years of experience, we are proud to be a valuable partner in the design, conduct, analysis and reporting of clinical trials through optimal study design, innovative statistical methodology and state-of-the-art integrated web systems that help achieve smooth and successful clinical development programs.